RxDoctor Payments Data

Shalini Verma, MD

Nephrology · Wilmington, DENPI 1972720225

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Johnson & Johnson at 30.6% of the total. Reporting peaked in 2022 at $479 and has fallen 78.7% since, to $102 in 2025. That places this record below the midpoint for nephrology clinicians in DE, where the typical reported total is $2,465.

$1,451in general payments, 2019–2025

Across 70 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$444
  • Novartis$369
  • E.r. Squibb & Sons, L.L.C.$214
  • Kestra Medical Technology Services, Inc.$106
  • Dexcom, Inc.$79
  • AstraZeneca$71
  • plus $169 from 4 others

What the payments were for

  • Food & beverage$1,451100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,451 in reported general payments places this provider in the 35th percentile of 49 nephrology providers in Delaware.

See all nephrology providers in Delaware

Medicare billing

Part B allowed, 2024
$145,595
Medicare patients
517
Services billed
1,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin49$38,779
FarxigaDapagliflozin Propanediol32$22,366
EliquisApixaban21$10,822
Calcitriol132$1,387
Potassium Chloride56$893
Metoprolol Succinate37$612
Amlodipine Besylate114$528
Losartan Potassium42$375
Lisinopril74$346
Bisoprolol Fumarate36$333
Hydralazine Hcl42$284
Cefdinir20$284
Furosemide94$253
Pantoprazole Sodium13$168
Atorvastatin Calcium17$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$71$22,36632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 49 nephrology providers in Delaware.

Other nephrology in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →